title: Mutation-driven drug development in melanoma.
abstract: OBJECTIVE
  The identification of mutations in signal transduction pathways that are central in melanoma pathophysiology has provided new therapeutic targets for drug development. The purpose of this review is to define those oncogenes for which there are preclinical data supporting clinical trials and to summarize results from clinical investigations.
  
  
  RESULTS
  CKIT mutations were first reported in 2005 but are present in only a small subpopulation of melanoma patients. The validation of inhibitors developed in gastrointestinal stromal tumors has taken several years, but recent evidence suggests that responses can be seen in CKIT mutant melanoma. First reported in 2002, BRAF is mutated in 50% of all melanomas and subsets of other cancers. The melanoma field is leading the clinical trials evaluating the value of targeting BRAF and MEK in BRAF mutant tumors. Results from the first clinical trial with a potent and selective BRAF inhibitor clearly show the therapeutic promise of this approach.
  
  
  CONCLUSIONS
  Larger clinical trials are needed to fully define the efficacy of BRAF and CKIT-directed therapy in melanoma, but early results suggest that this strategy will transform treatment options. Additional potential targets have been identified, and clinical trials evaluating novel drugs against them are underway.
authors.affiliation: Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA. ktflaherty@partners.org
authors.forename: Keith T
authors.initials: KT
authors.lastname: Flaherty
authors.forename: F Stephen
authors.initials: FS
authors.lastname: Hodi
authors.forename: Boris C
authors.initials: BC
authors.lastname: Bastian
mesh_terms: D000818:Animals; D015195:Drug Design; D006801:Humans; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics*; D009154:Mutation; D015398:Signal Transduction / Q000235:genetics*
references.citation: Lancet. 2006 Oct 14;368(9544):1329-38
references.pmid: 17046465
references.citation: Br J Cancer. 2006 Sep 4;95(5):581-6
references.pmid: 16880785
references.citation: Melanoma Res. 2009 Jun;19(3):156-66
references.pmid: 19434003
references.citation: J Invest Dermatol. 2006 Jan;126(1):154-60
references.pmid: 16417231
references.citation: Cancer Genet Cytogenet. 1999 Jan 1;108(1):81-3
references.pmid: 9973930
references.citation: Cancer Genet Cytogenet. 2008 Apr 15;182(2):116-21
references.pmid: 18406873
references.citation: Mol Cell Biol. 1985 Mar;5(3):582-5
references.pmid: 3887133
references.citation: Pigment Cell Melanoma Res. 2008 Aug;21(4):492-3
references.pmid: 18510589
references.citation: Clin Cancer Res. 2008 Nov 1;14(21):6821-8
references.pmid: 18980976
references.citation: J Clin Oncol. 1999 Jul;17(7):2105-16
references.pmid: 10561265
references.citation: Nature. 1984 Mar 1-7;308(5954):69-72
references.pmid: 6700714
references.citation: Melanoma Res. 2001 Feb;11(1):75-81
references.pmid: 11254118
references.citation: Clin Cancer Res. 2008 Dec 1;14(23):7726-32
references.pmid: 19047099
references.citation: PLoS One. 2009 May 27;4(5):e5717
references.pmid: 19492075
references.citation: Cancer Cell. 2008 Dec 9;14(6):485-93
references.pmid: 19061839
references.citation: J Clin Oncol. 2006 Sep 10;24(26):4340-6
references.pmid: 16908931
references.citation: Oncogene. 2007 Jul 12;26(32):4738-48
references.pmid: 17260012
references.citation: Nat Genet. 2009 Oct;41(10):1127-32
references.pmid: 19718025
references.citation: J Clin Oncol. 2006 Oct 10;24(29):4764-74
references.pmid: 16954519
references.citation: Clin Cancer Res. 2005 Mar 1;11(5):1983-9
references.pmid: 15756024
references.citation: Nature. 2009 Jan 29;457(7229):599-602
references.pmid: 19078957
references.citation: Oncogene. 2004 Aug 5;23(35):5968-77
references.pmid: 15195137
references.citation: J Natl Cancer Inst. 2003 Dec 17;95(24):1878-90
references.pmid: 14679157
references.citation: Int J Cancer. 2008 Jul 15;123(2):340-347
references.pmid: 18398842
references.citation: J Clin Oncol. 2009 Jun 10;27(17):2823-30
references.pmid: 19349552
references.citation: Cancer. 2006 May 1;106(9):2005-11
references.pmid: 16565971
references.citation: Melanoma Res. 2006 Dec;16(6):471-8
references.pmid: 17119447
references.citation: J Transl Med. 2012 Dec 10;10:246
references.pmid: 23228035
references.citation: Int J Cancer. 2006 Mar 15;118(6):1426-9
references.pmid: 16187281
references.citation: Mol Cancer Ther. 2008 Jun;7(6):1533-42
references.pmid: 18566224
references.citation: Nature. 2002 Jun 27;417(6892):949-54
references.pmid: 12068308
references.citation: Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20932-7
references.pmid: 18093943
references.citation: Cancer Res. 2003 Jul 15;63(14):3955-7
references.pmid: 12873990
references.citation: Cancer Res. 2003 Sep 15;63(18):5761-6
references.pmid: 14522897
references.citation: Oncogene. 2003 Jun 26;22(26):4092-101
references.pmid: 12821943
references.citation: BMC Cancer. 2006 Apr 01;6:85
references.pmid: 16579858
references.citation: Cancer Res. 2008 Jul 15;68(14):5743-52
references.pmid: 18632627
references.citation: N Engl J Med. 2005 Nov 17;353(20):2135-47
references.pmid: 16291983
references.citation: Br J Cancer. 2005 Apr 25;92(8):1398-405
references.pmid: 15846297
references.citation: J Clin Oncol. 2008 Apr 20;26(12):2046-51
references.pmid: 18421059
references.citation: Cancer Res. 2004 Oct 1;64(19):7099-109
references.pmid: 15466206
references.citation: Cancer Res. 2002 Dec 1;62(23):6997-7000
references.pmid: 12460918
references.citation: J Invest Dermatol. 2005 Dec;125(6):1242-51
references.pmid: 16354195
references.citation: Mol Cancer Ther. 2006 May;5(5):1136-44
references.pmid: 16731745